Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action

References

• Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev.3, CD001425 (2004).
   Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al.; for the AVOREN Trial investigators. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al.; for the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus interferon α-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol.28(13), 2144–2150 (2010).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al.; for the Global ARCC Trial. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al.; for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al.; for the RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer116(18), 4256–4265 (2010).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26(33), 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon α monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol.28(13), 2137–2143 (2010).
   PubMed Web of Science ®Google Scholar
• Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol.182(1), 29–34 (2009).
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer115, 61–67 (2009).
   PubMed Web of Science ®Google Scholar
• Porta C, Procopio G, Sabbatini R et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur. Urol. Suppl.8(4), 183 (2009) (Abstract 252).
   Google Scholar
• Vickers MM, Choueiri TK, Rogers M et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology76(2), 430–434 (2010).
   PubMed Web of Science ®Google Scholar
• Richter S, Pfister SD, Thüer D, Engelmann UH, Heidenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie31(Suppl. 4), 1–240 (2008) (Abstract V684).
   Google Scholar
• Sepulveda J, Maroto P, Andres R et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts. J. Clin. Oncol.26(Suppl.), 679s (2008) (Abstract 16100).
   Google Scholar
• Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol.54, 1373–1378 (2008).
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol.179, 81–86 (2008).
   PubMed Web of Science ®Google Scholar
• Zimmermann K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology76(5), 350–354 (2009).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Brick AJ, McDermott D et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann. Oncol.19(Suppl. 8), viii191–viii192 (2008) (Abstract 593P).
   Google Scholar
• Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon α-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(8), 1280–1289 (2009).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Cartenì G, Autorino R et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J. Clin. Oncol.27, 4469–4474 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia JA, Hutson TE, Elson P et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer116(23), 5383–5390 (2010).
   PubMed Web of Science ®Google Scholar
• Mancuso AP, Donato De Paola E, Catalano A et al. Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment. J. Clin. Oncol.27(Suppl.) (2009) (Abstract e16027).
   Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol.26(22), 3743–3748 (2008).
   PubMed Web of Science ®Google Scholar
• Shepard DR, Rini BI, Garcia JA et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 5123).
   Google Scholar
• Chang YS, Adnane J, Trail PA et al. Sorafenib (BAY 43–9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol.59(5), 561–574 (2007).
   PubMed Web of Science ®Google Scholar
• Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel–Lindau pathway in renal cell carcinoma. Clin. Cancer Res.12(24), 7215–7220 (2006).
   PubMed Web of Science ®Google Scholar
• Wiederkehr D, Howe CJ, Casciano R et al. Overall survival among metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring weights: analyses from the RECORD-1 Phase 3 trial. Eur. J. Cancer Suppl.7, 432 (2009) (Abstract P-7131).
   Google Scholar
• Jac J, Amato RJ, Giessinger S, Saxena S, Willis JP. A Phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J. Clin. Oncol.26(Suppl.), 277s (2008) (Abstract 5113).
   Google Scholar
• Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol.28(13), 2131–2136 (2010).
   PubMed Web of Science ®Google Scholar
• Gruenwald V, Seidel C, Fenner M, Heuser M, Ganser A. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5–7 March 2010 (Abstract 414).
   Google Scholar
• Rini BI, Hutson TE, Elson P et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5–7 March 2010 (Abstract 319).
   Google Scholar
• Ravaud A, Digue L, Trufflandier N, Smith D. VEGFR TKI ‘resistance’ or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann. Oncol.21(2), 431–432 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Weinberg VK, Claros C et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J. Clin. Oncol.26(Suppl.), 276s (2008) (Abstract 5109).
   Google Scholar
• Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer.7, 24–27 (2009).
   PubMed Web of Science ®Google Scholar
• Feldman DR, Ginsberg MS, Baum M et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.26(Suppl.), 274s (2008) (Abstract 5100).
   Google Scholar
• Kroog GS, Feldman DR, Kondagunta GV et al. Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(Suppl.), 243s (2009) (Abstract 5037).
   Google Scholar
• Escudier BJ, Negrier S, Gravis G et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA Phase II trial. J. Clin. Oncol.28(Suppl.), 15s (2010) (Abstract 4516).
   PubMedGoogle Scholar
• Dutcher JP, Wilding G, Hudes GR et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J. Clin. Oncol.26(Suppl.), 281s (2008) (Abstract 5127).
   Google Scholar
• Knox JJ, Kay AC, Schiff E et al. First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.28(Suppl. 15s), 39s (2010) (Abstract TPS232).
   Google Scholar
• Furge KA, MacKeigan JP, Teh BT. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol.11(6), 571–578 (2010).
   PubMed Web of Science ®Google Scholar